These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Botulinum A toxin for glabellar wrinkles. Dose and response. Hankins CL, Strimling R, Rogers GS. Dermatol Surg; 1998 Nov; 24(11):1181-3. PubMed ID: 9834736 [Abstract] [Full Text] [Related]
25. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment. de Almeida AR, da Costa Marques ER, Banegas R, Kadunc BV. Dermatol Surg; 2012 Sep; 38(9):1506-15. PubMed ID: 22804914 [Abstract] [Full Text] [Related]
26. Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials. Guo Y, Lu Y, Liu T, Zhou Y, Yang P, Zhu J, Chen L, Yang Q. Plast Reconstr Surg; 2015 Sep; 136(3):310e-318e. PubMed ID: 26313835 [Abstract] [Full Text] [Related]
28. An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation. Bhatnagar D, Conkling N, Rafailovich M, Phillips BT, Bui DT, Khan SU, Dagum AB. Skin Res Technol; 2013 Aug; 19(3):220-9. PubMed ID: 23565582 [Abstract] [Full Text] [Related]
29. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience. Farahvash MR, Arad S. J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691 [Abstract] [Full Text] [Related]
32. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, BOTOX Glabellar Lines I Study Group. J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480 [Abstract] [Full Text] [Related]
33. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Dessy LA, Fallico N, Mazzocchi M, Scuderi N. Am J Clin Dermatol; 2011 Dec 01; 12(6):377-88. PubMed ID: 21877763 [Abstract] [Full Text] [Related]
35. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, Flynn TC, Carruthers A. Dermatol Surg; 2010 Dec 01; 36 Suppl 4():2146-54. PubMed ID: 21134045 [Abstract] [Full Text] [Related]
37. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm. Conte A, Fabbrini G, Belvisi D, Marsili L, Di Stasio F, Berardelli A. Eur J Neurol; 2010 Mar 01; 17(3):449-55. PubMed ID: 19968711 [Abstract] [Full Text] [Related]
38. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Kane MAC, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB, Reloxin Investigational Group. Plast Reconstr Surg; 2009 Nov 01; 124(5):1619-1629. PubMed ID: 19584772 [Abstract] [Full Text] [Related]
39. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. J Am Acad Dermatol; 2004 Aug 01; 51(2):223-33. PubMed ID: 15280841 [Abstract] [Full Text] [Related]